Company intelligence / Profile preview
MindBio Therapeutics
- Ownership
- Private
- Development stage
- Phase 2
Overview
MindBio’s proprietary microdose LSD candidate MB22001 has shown promising results. In the completed Phase 2a trial for MDD, after eight weeks of treatment with MB22001 microdosing: "53% of depressed patients entered complete remission after eight weeks... Overall there was an impressive ~60% drop in depressive symptoms at week eight." Phase I showed positive safety/tolerability data plus improvements in mood and sleep metrics. Multiple randomized controlled Phase IIb trials are underway—one focused on MDD (~90 patients), another on late-stage cancer patients experiencing depression/anxiety/existential distress.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Psychedelic microdosing (proprietary titratable LSD formulation)Oral small molecule (MB22001)Digital therapeutics and wearables for monitoring
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on MindBio Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MindBio Therapeutics.